Bariatric/Metabolic Surgery for Diabetes: Lessons From the Past and Present

Jonathan Q. Purnell and Bruce M. Wolfe

Enter the surgeons again. Starting in the latter half of the last century, obesity became an increasingly prevalent medical problem in the U.S. and other developed nations. As obesity rates have risen, so has our understanding of the importance of excess fat storage in expression of insulin resistance and type 2 diabetes. In this issue of Diabetes Care, Buchwald and Buchwald (2) chronicle the history of surgical approaches to weight loss in patients with obesity and the subsequent, often dramatic improvement in hyperglycemia and type 2 diabetes these patients experience. In highlighting those surgeons whose key innovations led to today’s effective procedures, they can make it seem, in retrospect, that these innovations occurred in an orderly fashion. However, anatomic variations, some minor and some major, were constantly proposed and tested by surgeons. Opinions differed regarding the optimal length of the Roux limb or common channel. The duodenal switch was added to the biliopancreatic diversion in an effort to preserve the pylorus and reduce dumping symptoms. Only recently have common standards for these procedures been widely accepted, thereby assuring patients that regardless of which surgeon they see, both the specifics of the procedure and the outcomes from bariatric procedures will align with published data. Acknowledgment should also be given to the countless numbers of patients with obesity who, through their willingness (some might say their desperation), volunteered to undergo these procedures and either suffered the consequences or helped to establish their benefits.

However, the medical community has historically been wary of bariatric/metabolic approaches to diabetes management, citing a lack of high-quality evidence (e.g., randomized controlled trials) and failure to properly define the mechanisms of diabetes improvement. Buchwald and Buchwald (2) nicely chronicle the initial observational studies from single sites, followed by large prospective cohort studies and the now more than 10 randomized controlled trials that have 3- to 5-year follow-up data consistently showing superior weight loss and diabetes control, or equivalent control with far less diabetes medication use, following bariatric/metabolic procedures compared with intensive medical diabetes management. Counterarguments are given, though, that if patients lose weight through other means, they will achieve the same result. Even the earliest improvements in glucose control have been attributed to the large postoperative drop in calorie intake (3). Buchwald and Buchwald highlight this conceptual issue early in their review. That is, are these procedures simply weight-loss inducing (hence “bariatric”) or do they have weight-independent...
effects (“metabolic”)? Further, do their mechanisms of action fit simply into either “restrictive” or “malabsorptive” descriptors? As the authors point out, depending on the procedure, it is all of these and more. Regardless of the heterogeneity in entry characteristics of participants and the de-erogeneity in entry characteristics of depending on the procedure, it is all of 

- loss (4) and weight loss (4) and weight loss–dependent mechanisms (5). Candidate mechanisms abound, ranging from changes in adipokines to a rapidly expanding array of gastrointestinal factors that include not just the previously mentioned gut hormones (6) but also changes in bile acid levels (7,8), nutrient sensing (9), and the microbiome (10). The interface between the gastrointestinal tract and glucolipid metabolism is perhaps one of the most exciting areas of diabetes research today, calling for the integration of multiple disciplines including neuroendocrinology, nutrition, microbiology, hepatology, and metabolism.

Not covered in the review (2) are several areas of common ground shared by bariatric/metabolic surgery and medical management. For example, microvascular and macrovascular complications of diabetes have been shown to improve with medical management (11, 12) as well as bariatric/metabolic surgeries (13), and reductions in cardiovascular events and total mortality have been noted with both (14–18). And while the sleeve gastrectomy and gastric bypass procedures are effectively irreversible, so is committing a patient to lifelong treatment with metformin or insulin. In both cases, diabetes is not “cured” but managed. Finally, variable glycemic responses between individuals occur regardless of which treatment is chosen, as does progressive disease worsening in the long term. For those treated medically, first-line drugs give way to combination therapies over time (19). In the case of bariatric/metabolic surgery, diabetes recurrence after initial remission can approach 40% during long-term follow-up (20–22). Underlying this individual responsiveness and disease progression is, likely, an ongoing decline in β-cell function despite continued treatment (23–25). Similarly, recent data acquired after gastric bypass have shown this procedure (26,27) to now be among a handful of interventions (28) demonstrated to improve islet cell secretory response in patients with diabetes, although that capacity remains tenuous (26,29) and diabetes appears poised to recur with worsening insulin resistance, such as with weight regain. Ironically, if improvement in diabetes outcomes is the primary goal, then bariatric/metabolic surgery should probably be considered even earlier in the disease course, such as in patients with obesity and prediabetes, when the capacity to preserve or restore islet cell function is greatest. However, this would add considerable strain to an already contentious debate regarding health care resource allocation and utilization in the U.S.

The review by Buchwald and Buchwald (2) tends to pass lightly over the complications of bariatric/metabolic procedures, giving the impression that they were anticipated or have been resolved. Not mentioned is a major surgical innovation that led to dramatically improved patient safety, which was the widespread adoption of minimally invasive (laparoscopic) techniques in the 1990s (30). Since then, the immediate surgical risk has been lowered to acceptable levels and is on par with other routine gastrointestinal procedures, such as cholecystectomies (31). However, the determination of the prevalence and severity of longer-term complications, including gastrointestinal complications and bone health, remains a work in progress.

It is fitting that the scientific and clinical communities are returning to the gastrointestinal tract to better understand and manage type 2 diabetes. At many academic centers, surgeons are again partnering with physiologists to continue the tradition of Banting and Macleod. As Buchwald and Buchwald point out, we should not necessarily consider current procedures to be “the last word”; further refinements may lead to safer patient outcomes and even newer breakthroughs in the physiology and treatment of diabetes. Future procedures will still need to be guided by the best science, which will require rigorous training and multidisciplinary research that no doubt surgeons will continue to lead.

Duality of Interest. J.Q.P. serves on an advisory board for Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.

References
1. Rehfeld JF. A centenary of gastrointestinal endocrinology. Horm Metab Res 2004;36:735–741
2. Buchwald H, Buchwald JN. Metabolic (bariatric and nonbariatric) surgery for type 2 diabetes: a personal perspective review. Diabetes Care 2019;42:331–340
3. Isbell J, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 2010;33:1438–1442
4. Bradley D, Conte C, Mittlendonnder B, et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest 2012;122:4667–4674
5. Purnell JQ, Seiter F, Wahed AS, et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. Diabetes Care 2016;39:1101–1107
6. Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 2013;98:4391–4399
7. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013;98:E708–E712
8. Bozadjieva N, Heppner KM, Seeley RJ. Targeting FXR and FGF19 to treat metabolic diseases—lessons learned from bariatric surgery. Diabetes 2018;67:1720–1728
9. Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 2012;18:950–955
10. Liu H, Hu C, Zhang X, Jia W. Role of gut microbiota, bile acids and their cross-talk in the effects of bariatric surgery on obesity and type 2 diabetes. J Diabetes Investig 2018;9:13–20
11. Nathan DM, Genuith S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
12. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
13. Carlsson LMS, Sjoholm K, Karlsson C, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 2017;5:271–279

Funding. This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK103842.
14. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
15. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322
16. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753–761
17. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with cardiovascular and macrovascular complications. JAMA 2014;311:2297–2304
18. Fisher DP, Johnson E, Haneuse S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018;320:1570–1582
19. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):573–585
20. Sjöström L, Lindroos AK, Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693
21. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102
22. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017;377:114–1155
23. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–1258
24. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443
25. Kahn SE, Lachin JM, Zinman B, et al.; ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552–1560
26. Purnell JQ, Johnson GS, Wahed AS, et al. Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia 2018;61:1142–1154
27. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709–1716
28. Page KA, Reisman T. Interventions to preserve β-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252–260
29. Dutia R, Brakoniecki K, Bunker P, et al. Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 2014;63:1214–1223
30. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001;234:279–289; discussion 289–291
31. Flum DR, Belle SH, King WC, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361:445–454